Having a treatment available and being able to access it are two very different things.

The Guardian recently highlighted research showing that while 91% of surveyed healthcare providers reported access to red blood cell exchange (RBCX), fewer than 3% of U.S. patients with sickle cell disease receive it annually. Behind these numbers are families navigating challenges with care coordination, blood availability, insurance, distance, and access to experienced care teams. Every person’s treatment needs are different. What matters is that patients understand their options and can access the care that is appropriate for them. At MTS Sickle Cell Foundation, we believe families deserve clear information, coordinated care, and practical support to overcome the barriers they face. Thank you to The Guardian for bringing attention to this issue and to Terumo BCT for amplifying the conversation. Available care must become accessible care. Read the article: "The Guardian" https://www.theguardian.com/society/2026/sep/27/sickle-cell-patients-red-blood-cell-exchange #SickleCellDisease #HealthEquity #AccessToCare